Coherus Oncology, Inc. (CHRS) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. Coherus Oncology, Inc. is a commercial-stage innovative oncology company focused on its approved PD-1 inhibitor, LOQTORZI (toripalimab-tpzi), and a pipeline of two mid-stage clinical candidates: casdozokitug (anti-IL-27) and tagmokitug (anti-CCR8). The company has divested its biosimilar franchises (UDENYCA, YUSIMRY, CIMERLI), with results from these businesses classified as discontinued operations.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Net Revenue (Continuing) | $14.3 million | $10.3 million | $26.6 million | $17.9 million |
| Net Loss (Continuing) | $(33.3) million | $(44.9) million | $(70.3) million | $(92.3) million |
| Net Income (Discontinued) | $12.7 million | $342.6 million | $11.3 million | $333.5 million |
| Net Income (Loss) Total | $(20.6) million | $297.8 million | $(59.0) million | $241.2 million |
| Gross Margin (Continuing) | 70% | 67% | 70% | 66% |
| Cash & Marketable Securities | $105.3 million (as of June 30, 2026) | |||
| Total Debt (2029 Term Loan) | $37.2 million (net carrying value) | |||
| Accumulated Deficit | $1.44 billion |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue from continuing operations increased 39% year-over-year for the quarter and 49% year-over-year for the six months, driven primarily by volume growth of LOQTORZI.
- Expense Reduction: Research and Development (R&D) expenses decreased 19% for the quarter and 15% for the six months compared to the prior year, due to lower employee-related costs and reduced infrastructure spending. Selling, General, and Administrative (SG&A) expenses decreased 19% and 15%, respectively, following the exit from the biosimilar business.
- Discontinued Operations Impact: The significant net income in Q2 2025 ($342.6 million) was driven by a one-time gain on the sale of the UDENYCA franchise. Q2 2026 discontinued income ($12.7 million) reflects only residual transition services and adjustments, resulting in a net loss for the consolidated entity in 2026 compared to a net profit in 2025.
- Capital Raise: In Q1 2026, the company completed a public offering of 32.9 million shares, raising net proceeds of $53.6 million.
Guidance, Outlook, and Risks
- Liquidity: Management believes current cash, cash equivalents, and marketable securities ($105.3 million) are sufficient to fund operations for at least 12 months. However, the company expects to require additional funding to complete clinical trials and commercialize pipeline candidates.
- Outlook: The company expects 2026 net revenue from continuing operations to be higher than 2025 due to LOQTORZI growth. Fixed R&D and SG&A expenses are expected to be lower in 2026 than 2025.
- Key Risks:
- Profitability: Limited history of profitability; reliance on LOQTORZI sales and future capital raises.
- Competition: LOQTORZI faces competition from other PD-1/PD-L1 inhibitors (e.g., Keytruda, Opdivo) and chemotherapy in nasopharyngeal carcinoma.
- Regulatory & Manufacturing: Risks associated with transitioning biomanufacturing from offshore to onshore (U.S.) and potential FDA disruptions.
- UDENYCA Earnouts: The company is eligible for two potential earnout payments of $37.5 million each from the UDENYCA sale, contingent on net sales thresholds that were not met as of June 30, 2026.
Investor Verification Checklist
- Verify the sustainability of LOQTORZI revenue growth rates and market share in the nasopharyngeal carcinoma (NPC) indication.
- Confirm the timeline and regulatory status of the onshoring initiative for LOQTORZI manufacturing.
- Monitor progress on clinical trials for pipeline candidates casdozokitug and tagmokitug, specifically enrollment and safety data.
- Assess the likelihood of receiving the $75 million in potential UDENYCA earnout payments based on Intas Pharmaceuticals' reported sales.
- Review the company's cash burn rate relative to the $105.3 million cash balance to determine the timing of future capital raises.